
    
      To evaluate the efficacy, safety and acceptability of an interferon-sparing strategy with
      sofosbuvir and ribavirin for the treatment of recently acquired HCV infection.

      An open label single arm multicentre study Treatment of participants: Sofosbuvir 400mg daily
      with weight based ribavirin (1000mg <75 kg, 1200mg >/= 75kg) Duration of treatment will be 6
      weeks for all subjects followed by 52 weeks of observational follow-up Total study duration =
      58 weeks Primary endpoint: SVR 12
    
  